Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Autor: Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis

Publikováno v: RMD Open, Vol 10, Iss 4 (2024)

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic d

Externí odkaz: https://doaj.org/article/876c49e5e08a4163a919ba3850e5bc79

Management of a patient with common variable immunodeficiency and hepatopathy

Autor: Lea Grümme, Hendrik Schulze-Koops

Publikováno v: Allergy, Asthma & Clinical Immunology, Vol 19, Iss 1, Pp 1-6 (2023)

Abstract Background Common variable Immunodeficiency (CVID) is a primary immunodeficiency disorder and the most common form of severe antibody deficiency. Both children and adults are affected and clinical manifestations vary widely. Often, CVID mani

Externí odkaz: https://doaj.org/article/859a78267eeb40119b998c8015cc68db

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases

Autor: Tobias Alexander, Hendrik Schulze-Koops, Ulf Müller-Ladner, Rebecca Fischer-Betz, Martin Aringer, Rieke Alten, Petra Saar, Tim Schmeiser, Marina Backhaus, Stephanie Finzel, Cornelia Glaser, Hildrun Haibel, Hanns-Martin Lorenz, Gamal Chehab, Christof Specker, Reinhard E Voll, Anja Strangfeld, Norbert Blank, Matthias Braun, Alexander Pfeil, Rebecca Hasseli, Andreas Krause, Anne Constanze Regierer, Peer Aries, Ioana Andreica, Jacqueline Detert, Elvira Decker, Urs Hartmann, Joerg Henes, Kirsten de Groot, JOACHIM GEORGI, Hans Bastian, Christoph Fiehn, Martin Feuchtenberger, Martin Fleck, Christian Blum, Mathias Grunke, Martin Bohl-Bühler, Georg Gauler, Bimba Franziska Hoyer, Guido Hoese, Janine Günther, Matthias Braunisch, Jutta G. Richter, Sabine Reckert, Anett Gräßler, Andreas Kapelle, Silke Osiek, Anna Knothe, Jan Brandt-Jürgens, Anja Maltzahn, Fredrik Albach, Annette Alberding, Susanne Aman, Christopher Amberger, Michaela Amberger, Bianka Andermann, Nils Anders, Jan Andresen, Nikolaos Andriopoulos, Elizabeth Arauj, Uta Arndt, Sarah Avemarg, Christoph Baerwald, Erich Bärlin, Nora Bartholomä, Michael Bäuerle, Jutta Bauhammer, Christine Baumann, Klaus Becker, Heidemarie Becker, Michaela Bellm, Sylvia Berger, Andrea Berghofen, Gerhard Birkner, Daniel Blendea, Hans Bloching, Sebastian Blötz, Stephanie Boeddeker, Susanne Bogner, Lara Bohnen, Ilka Bösenberg, Nicole Böttcher, Diana Braun, Jan Philipp Bremer, Matthias Broll, Andreas Bruckner, Veronika Brumberger, Martin Brzank, Sahra Büllesfeld, Sandra Burger, Michaela Christenn, Anne Claußnitzer, Frank Demtröder, Rainer Dörfler, Elke Drexler, Valeria Dudics, Edmund Edelmann, Roman Eder, Christina Eisterhues, Joachim Michael Engel, Brigitte Erbslöh-Möller, Miriam Feine, Samantha Ferdinan, Claudia Franke, Stefanie Freudenberg, Christian Fräbel, Petra Fuchs, Regina Gaissmaier, Ino Gao, Oliver Gardt, Katrin Geißler, Karolina Gente, Jasmin Gilly, Yannik Gkanatsas, Agnes Gniezinski- Schwister, Rahel Gold, Norman Görl, Ralf Görlitz, Karl-Heinz Göttl, Beate Göttle, Ricardo Grieshaber Bouyer, Gisela Grothues, Florian Günther, Mirjam Haag, Linda Haas, Anna Haas-Wöhrle, Denitsa Hadjiski, Till Hallmann-Böhm, Peter Härle, Charlotte Hasenkamp, Maura-Maria Hauf, Matthias Hauser

Publikováno v: RMD Open, Vol 9, Iss 2 (2023)

Objective To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs).Methods Data from the physician-reported German COVID-19-IRD registry collected between

Externí odkaz: https://doaj.org/article/bcd65462c49f49369021f75255aee09c

The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis

Autor: Christof Iking-Konert, Pia Wallmeier, Sabrina Arnold, Sabine Adler, Kirsten de Groot, Bernhard Hellmich, Bimba F. Hoyer, Konstanze Holl-Ulrich, Gabriele Ihorst, Margit Kaufmann, Ina Kötter, Ulf Müller-Ladner, T. Magnus, Jürgen Rech, Fabian Schubach, Hendrik Schulze-Koops, Nils Venhoff, Thorsten Wiech, Peter Villiger, Peter Lamprecht

Publikováno v: BMC Rheumatology, Vol 5, Iss 1, Pp 1-7 (2021)

Abstract Background Vasculitides comprise a group of rare diseases which affect less than 5 in 10.000 individuals. Most types of vasculitis can become organ- and life-threatening and are characterized by chronicity, high morbidity and relapses, altog

Externí odkaz: https://doaj.org/article/8f59c30451b24487839dad2ba4d31aca

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

Autor: Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Maya H. Buch, Eugeniusz J. Kucharz, Yannick Allanore, Arthur Kavanaugh, Philip Young, Goran Babic

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019)

Abstract Background Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe chronic plaque-type psoriasis. Met

Externí odkaz: https://doaj.org/article/f9341c15b3f54d4a8f66895ebc1b7a85